Cwm, LLC Madrigal Pharmaceuticals, Inc. Transaction History

Cwm, LLC

$23.3 Billion
Q3 2024

A detailed history of Cwm, LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Cwm, LLC holds 65 shares of MDGL stock, worth $20,048. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 103 36.89%

Holding current value

$20,048

Previous $29,000 51.72%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 08, 2024	SELL	$212.22 - $292.96 $8,064 - $11,132	-38 Reduced 36.89%	65 $14,000
Q2 2024 Jul 09, 2024	BUY	$193.33 - $291.99 $2,126 - $3,211	11 Added 11.96%	103 $29,000
Q1 2024 Apr 05, 2024	BUY	$171.37 - $283.23 $6,683 - $11,045	39 Added 73.58%	92 $25,000
Q4 2023 Feb 01, 2024	SELL	$120.4 - $237.13 $2,046 - $4,031	-17 Reduced 24.29%	53 $12,000
Q3 2023 Oct 11, 2023	SELL	$146.04 - $225.78 $146 - $225	-1 Reduced 1.41%	70 $10,000
Q2 2023 Aug 03, 2023	BUY	$203.88 - $312.0 $3,465 - $5,304	17 Added 31.48%	71 $16,000
Q1 2023 Apr 28, 2023	BUY	$231.06 - $307.08 $924 - $1,228	4 Added 8.0%	54 $13,000
Q2 2022 Jul 28, 2022	SELL	$58.04 - $100.2 $1,044 - $1,803	-18 Reduced 26.47%	50 $4,000
Q1 2022 Apr 21, 2022	BUY	$55.89 - $101.89 $670 - $1,222	12 Added 21.43%	68 $7,000
Q4 2021 Jan 31, 2022	BUY	$72.34 - $95.09 $3,182 - $4,183	44 Added 366.67%	56 $5,000
Q3 2020 Oct 19, 2020	BUY	$99.78 - $124.21 $1,197 - $1,490	12 New	12 $1,000
Q1 2019 Apr 22, 2019	SELL	$103.48 - $143.84 $310 - $431	-3 Closed	0 $0
Q4 2018 Jan 25, 2019	BUY	$94.77 - $215.54 $284 - $646	3 New	3 $0

Others Institutions Holding MDGL

# of Institutions

297

Shares Held

22M

Call Options Held

819K

Put Options Held

640K

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.28B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account